期刊
EXPERT REVIEW OF ANTICANCER THERAPY
卷 17, 期 4, 页码 369-386出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14737140.2017.1285230
关键词
Neuroblastoma; INRG; MYCN; ALK; immunotherapy; MIBG; dinutuximab
类别
资金
- NCI NIH HHS [K12 CA090433] Funding Source: Medline
Introduction: Children with neuroblastoma have widely divergent outcomes, ranging from cure in >90% of patients with low risk disease to <50% for those with high risk disease. Recent research has shed light on the biology of neuroblastoma, allowing for more accurate risk stratification and treatment reduction in many cases, although newer treatment strategies for children with high-risk and relapsed neuroblastoma are needed to improve outcomes.Areas covered: Neuroblastoma epidemiology, diagnosis, risk stratification, and recent advances in treatment of both newly diagnosed and relapsed neuroblastoma.Expert commentary: The identification of newer tumor targets and of novel cell-mediated immunotherapy agents may lead to novel therapeutic approaches, and clinical trials for regimens designed to target individual genetic aberrations in tumors are underway. A combination of therapeutic modalities will likely be required to improve survival and cure rates for patients with high-risk neuroblastoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据